B. Basu

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
B Basu, B. Basu, Bristi Basu
Publication record
125 papers · 2,536 citations · H-index 27

PAPERS

TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
20257 citationsauthor #13
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial
202333 citationsauthor #2
Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
20235 citationsauthor #10
A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).
202314 citationsauthor #2
Surgical outcomes of gallbladder cancer: the OMEGA retrospective, multicentre, international cohort study
202344 citationsauthor #14
Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade
20230 citationsauthor #15
Clinical trials for pancreatic cancer
20230 citationsauthor #2
Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma
20239 citationsauthor #7
Abstract CT201: Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors
20220 citationsauthor #2
Radiomic and Volumetric Measurements as Clinical Trial Endpoints—A Comprehensive Review
20226 citationsauthor #5
Abstract A074: Developing a novel in vivo model of pancreatic ductal adenocarcinoma using primary tumor samples and humanised mouse models
20220 citationsauthor #3
850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies
20221 citationsauthor #9
A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
20226 citationsauthor #28
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer
202227 citationsauthor #23
Dynamics in Circulating y -55Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial
20220 citationsauthor #13
Evaluation of membrane type 1 metalloproteinase (MT1-MMP/MMP14) expression as a prognostic biomarker in patients with solid tumours screened for a Phase I/II trial
20220 citationsauthor #11
Imaging Glioblastoma Metabolism by Using Hyperpolarized [1-13C]Pyruvate Demonstrates Heterogeneity in Lactate Labeling: A Proof of Principle Study
202235 citationsauthor #23
774 A phase 1 study exploring the safety and tolerability of the small molecule PD-L1 inhibitor, INCB086550, in patients with select advanced tumors
20223 citationsauthor #12
LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.
202153 citationsauthor #9
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
202151 citationsauthor #48
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial
202129 citationsauthor #12
Referee acknowledgement for 2020
20210 citationsauthor #107
Abstract 1730: Up-regulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and cancer patients
20211 citationsauthor #18
LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.
202118 citationsauthor #11
Abstract CT214: ATRiUM: A first-in-human dose escalation phase I trial of ceralasertib (AZD6738) and gemcitabine as combination therapy
20210 citationsauthor #2
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
202165 citationsauthor #20
The impact of COVID-19 on clinical cancer care: An individual-patient level analysis.
20210 citationsauthor #16
297 Leap-005: evaluating the safety and efficacy of lenvatinib and pembrolizumab in patients previously treated for ovarian cancer, a multi-cohort phase 2 study
20204 citationsauthor #7
STARPAC clinical trial
20201 citationsauthor #2
Real-world experience of regorafenib in patients with hepatocellular carcinoma: A multicenter United Kingdom study.
20201 citationsauthor #8
Hyperpolarized 13C MRI of Tumor Metabolism Demonstrates Early Metabolic Response to Neoadjuvant Chemotherapy in Breast Cancer
202045 citationsauthor #22
Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer
202020 citationsauthor #2
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
2020209 citationsauthor #7
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
202015 citationsauthor #3
A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer.
20201 citationsauthor #19
First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
20202 citationsauthor #4
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2020114 citationsauthor #5
Pancreatic Resectability in Cancers with Known Limited Extension (PRICKLE) – a single-arm phase 2a study of gemcitabine (Gem) plus Nab-paclitaxel (NabP) for borderline (un)resectable pancreatic ductal adenocarcinoma (BrPDAC)
20200 citationsauthor #1
Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma
202014 citationsauthor #5
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
20200 citationsauthor #3
Imaging breast cancer using hyperpolarized carbon-13 MRI
2020160 citationsauthor #32
Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI
202013 citationsauthor #10
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
202051 citationsauthor #21
2 Efficacy and safety of lenvatinib plus pembrolizumab in patients with previously treated ovarian cancer in the multicohort phase 2 LEAP-005 study
20203 citationsauthor #7
Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers.
202056 citationsauthor #33
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
2020179 citationsauthor #2
Somatic chromosomal number alterations affecting driver genes inform in-vitro and clinical drug response in high-grade serous ovarian cancer
20201 citationsauthor #23
The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma – a substudy of the SORAMIC trial
202017 citationsauthor #10
Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
20201 citationsauthor #4
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
201958 citationsauthor #15
STAR-PAC: Phase I clinical trial repurposing all trans retinoic acid (ATRA) as stromal targeting agent in a novel drug combination for pancreatic cancer
20192 citationsauthor #2
First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP-α, in patients with advanced hepatocellular cancer (HCC)
20194 citationsauthor #3
Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial
201958 citationsauthor #8
Early derangement of the international normalized ratio (INR) predicts liver insufficiency following liver resection for hepatocellular carcinoma
20180 citationsauthor #6
Hyperpolarized carbon-13 magnetic resonance spectroscopic imaging: a clinical tool for studying tumour metabolism.
201836 citationsauthor #7
Feasibility of metabolic imaging of hyperpolarized 13C-pyruvate in human breast cancer
20183 citationsauthor #8
Drug development and clinical trial design in pancreatico-biliary malignancies.
20186 citationsauthor #3
A phase I trial of the c-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
20183 citationsauthor #2
Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.
20186 citationsauthor #3
738PStrong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC)
20173 citationsauthor #7
First-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer.
20174 citationsauthor #3
Development of a prognostic model that predicts survival following Whipple's resection for ampullary adenocarcinoma.
20170 citationsauthor #5
Referee Acknowledgement for 2016
20170 citationsauthor #83
P3.02c-003 TAX-TORC: The novel combination of weekly paclitaxel and the dual mTORC1/2 inhibitor AZD2014 for the treatment of squamous NSCLC.
20173 citationsauthor #8
An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.
201711 citationsauthor #16
Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer
201712 citationsauthor #6
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).
20173 citationsauthor #3
TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.
20170 citationsauthor #2
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.
20167 citationsauthor #14
CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.
20160 citationsauthor #14
Abstract B40: Evaluation of the combination of AZD2014 and olaparib in pancreatic cancer cells
20160 citationsauthor #4
PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC)
20165 citationsauthor #1
Symptoms and Patient Factors Associated with Diagnostic Intervals for Pancreatic Cancer: A Prospective Cohort Study
20161 citationsauthor #5
TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer
20160 citationsauthor #2
Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study
2016131 citationsauthor #5
STAR_PAC: A Phase 1B study repurposing ATRA as stromal targeting agent along with gemcitabine and nab¬Paclitaxel for pancreatic cancer
20165 citationsauthor #10
Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations
201613 citationsauthor #24
PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).
201616 citationsauthor #5
Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience too toxic for relapse?
20163 citationsauthor #6
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience
201546 citationsauthor #6
Abstract CT204: Preliminary results from PiSARRO, a phase Ib/II study of APR-246, a mutant p53 reactivating small molecule, in combination with standard chemotherapy in platinum-sensitive ovarian cancer
20151 citationsauthor #5
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
2015114 citationsauthor #1
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
201513 citationsauthor #3
Advanced pancreatic cancer
20150 citationsauthor #1
EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC).
20156 citationsauthor #4
Abstract CT138: Translating preclinical observations to the clinic: Combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer
20152 citationsauthor #4
468PPHASE I MULTICENTRE TAX-TORC TRIAL OF THE DUAL MTORC1/2 INHIBITOR AZD2014 (A) PLUS WEEKLY PACLITAXEL (P) IN PATIENTS (PTS) WITH SOLID TUMOURS (CRUKD/12/013).
20141 citationsauthor #1
Angiogenesis: focus on renal cancer
20140 citationsauthor #1
TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors.
20142 citationsauthor #19
Ask the Experts: Learning from failures and successes, and identifying patients that may benefit from antiangiogenesis therapy
20140 citationsauthor #1
A phase I trial of the ɣ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).
20149 citationsauthor #2
Multiple choice questions: ANSWERS
20144 citationsauthor #1
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors
201371 citationsauthor #12
Review of patients with adrenocortical carcinoma at a tertiary referral centre
20130 citationsauthor #8
PARP Inhibitors
201212 citationsauthor #1
Association of creatine kinase and skin toxicity in phase I trials of anticancer agents
201218 citationsauthor #13
Association of creatine kinase and skin toxicity in phase I trials of anticancer agents
201218 citationsauthor #12
The role of angiogenesis inhibitors in the management of melanoma.
201221 citationsauthor #2
First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.
201234 citationsauthor #5
Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials
20120 citationsauthor #1

TIMELINE

1999 0 citations

2004 0 citations

2005 0 citations

2006 16 citations

2007 0 citations

2009 30 citations

2010 168 citations

2011 83 citations

2012 228 citations

2013 71 citations

2014 16 citations

2015 182 citations

2016 181 citations

2017 36 citations

2018 54 citations

2019 122 citations

2020 907 citations

2021 217 citations

2022 78 citations

2023 105 citations

2025 7 citations

Unknown 21 citations

B. Basu

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT